Arterial hypertension is one of the major causes of cardiovascular morbidity and mortality
worldwide. Effective and sustained reduction in blood pressure is essential to reduce …

Triple therapy with lipid‑lowering, antihypertensive, and antiplatelet agents reduces the risk
of recur‑rent cardiovascular fatal and nonfatal events, cardiovascular mortality, and total …

Although the cardiovascular (CV) polypill concept is not new and several guidelines state
that a CV polypill should be considered an integral part of a comprehensive CV disease …

Οne of the highlights of the current recommendations of the European Society of Cardiology
(ESC) and the European Society of Hypertension (ESH) for the management of arterial …

Introduction Non-angiotensin converting enzyme mechanisms of angiotensin II production
remain underappreciated in part due to the success of current therapies to ameliorate the …

The main objective of cardiovascular disease (CVD) prevention is to reduce morbidity and
mortality. Despite recommendations on evidence-based pharmacological treatment and …

Cardiovascular disease (CVD) is the primary cause of death and disability worldwide.
Although age-standardized CVD mortality rates decreased globally by 14.5% between 2006 …

COVID-19 has had a negative impact on the health care of patients with cardiovascular
disease and patients at high risk of cardiovascular disease. The restrictions affecting access …

Aims The retrospective NEPTUNO study evaluated the effectiveness of the Centro Nacional
de Investigaciones Cardiovasculares (CNIC)-polypill (including acetylsalicylic acid, ramipril …

Elevated blood pressure (BP) is the largest contributor to the incident cardiovascular
disease worldwide. Despite explicit guideline recommendations for the diagnosis and …